Biopharmaceuticals Contract Manufacturing Market

Biologics Contract Manufacturing Market Size, Share, Trends, Analysis and Forecast 2027


According to the new market research report “Biologics Contract Manufacturing Market (By Source (Mammalian, Non-Mammalian), By Product (Biologics, Biosimilars), By Service (Process Development) – Global Forecast to 2027″, published by Nova one advisor, the global Biologics Contract Manufacturing Market is projected to reach USD 26.4 Billion by 2027 from USD 15.1 billion in 2020, growing at a CAGR of 6.9% during the forecast period.

Growth Factors:

The success of the biopharmaceutical market can be majorly attributed to the contract manufacturers. Reduction in the overall investment required to bring a new drug product to market, providing access to expensive technologies, quick entry of products in the markets, and greater flexibility are some advantages offered by Contract Manufacturing Organizations (CMOs), which have prompted the companies to outsource their biopharmaceutical manufacturing. Furthermore, with a perpetual expansion of the biopharmaceutical industry, companies are facing production issues, such as lack of expertise and sophisticated equipment, while practicing in-house manufacturing.

Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors that are driving partnership between large molecule manufacturers and Contract Manufacturing Organizations (CMOs). Contract manufacturers are engaged in broadening their service portfolio to meet the company demands with respect to regulatory standards and new services.

 The reliance of companies on CMOs for the production of biologics and biosimilars is expected to rise over the forecast period as a consequence of changes adopted by the CMOs. This is evident through growing investment in collaborations of companies with CMOs as well as continuous efforts taken up for expanding the service portfolio.

The supply chain of biopharmaceuticals remained robust and was largely unaffected worldwide during the coronavirus outburst. Also, biopharmaceutical contract manufacturers are observing increased demand related to the Covid-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the global market. For instance, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca’s Covid-19 vaccine candidate, AZD1222.

Get your Customized Research Report@

Report Coverage

Report Scope Details
Market Size USD 26.4 Billion by 2027
Growth Rate CAGR of 6.9% From 2021 to 2027
Base Year 2020
Forecast Period 2021 to 2027
Historic Data 2017 to 2020
Report coverage Growth Factors, Revenue Status, Competitive Landscape,  and Future Trends
Segments Covered Source, service, product and Region
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)
Companies Mentioned Boehringer Ingelheim GmbH; Lonza; Inno Biologics Sdn Bhd; Rentschler Biotechnologie GmbH; JRS Pharma; AGC Biologics; ProBioGen; Fujifilm Diosynth Biotechnologies U.S.A., Inc.; Toyobo Co., Ltd.; Samsung BioLogics; Thermo Fisher Scientific, Inc.; Binex Co., Ltd.; WuXi Biologics; AbbVie, Inc..

Key Players:

This report provides detailed company profiles of the key market players. This research report also highlights the competitive landscape of the Biologics Contract Manufacturing market and ranks noticeable companies as per their occurrence in diverse regions across globe and crucial developments initiated by them in the market space. This research study also tracks and evaluates competitive developments, such as collaborations, partnerships, and agreements, mergers and acquisitions; novel product introductions and developments, promotion strategies and Research and Development (R&D) activities in the marketplace. The competitive profiling of these players includes business and financial overview, gross margin, production, sales, and recent developments which can aid in assessing competition in the market.

Some of the prominent players in the Biopharmaceuticals Contract Manufacturing Market include:  Boehringer Ingelheim GmbH; Lonza; Inno Biologics Sdn Bhd; Rentschler Biotechnologie GmbH; JRS Pharma; AGC Biologics; ProBioGen; Fujifilm Diosynth Biotechnologies U.S.A., Inc.; Toyobo Co., Ltd.; Samsung BioLogics; Thermo Fisher Scientific, Inc.; Binex Co., Ltd.; WuXi Biologics; AbbVie, Inc.

Segments Covered in the Report

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2027 and covers subsequent region in its scope:

  • By Source
    • Mammalian
    • Non-mammalian
  • By Service
    • Process Development
      • Downstream
      • Upstream
    • Fill & Finish Operations
    • Analytical & QC Studies
    • Packaging
  • By Product
    • Biologics
      • Monoclonal Antibodies (MABs)
      • Recombinant Proteins
      • Vaccines
      • Antisense, RNAi, & Molecular Therapy
      • Others
    • Biosimilars

Regional Segmentation:

– North America Region (U.S., Canada, Mexico)

– Europe Region (Germany, UK, France, Russia, Italy, Rest of Europe)

– Asia-Pacific Region (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

– South America Region (Brazil, Argentina, Columbia, Rest of South America)

– The Middle East & Africa Region (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

View Detail Information with Complete TOC@

Growth of Biopharmaceutical Industry and Promising Drug Pipeline

Increase in biopharmaceutical sales and promising drug pipeline drive the overall need of biologics clinical development and manufacturing services across the whole spectrum, from pre-clinical services to commercial manufacturing. Over 3,500 recombinant proteins and antibodies are in pre-clinical and clinical trials, including treatments that have been approved. An increasing number of molecules are being developed by small and virtual biotech companies. These companies do not have the in-house manufacturing capacity and expertise to bring their candidates to market, and therefore have a higher propensity to outsource. Presently, these emerging biopharma companies constitute around 80% of the development pipeline.

Increase in Adoption of Monoclonal Antibodies

In terms of type, the global biologics contract manufacturing market has been classified into monoclonal antibodies, recombinant proteins, vaccines, molecular therapy and others (RNAi, antisense RNA, etc.). The monoclonal antibodies segment was valued at US$ 5.1 Bn in 2020 and is projected to reach US$ 17.0 Bn by 2027, expanding at a CAGR of 11.2% from 2021 to 2027. The segment’s dominance can be attributed to increase in adoption of monoclonal antibodies for large unmet medical needs in the fields of oncology and autoimmune disorders.

Scope of the Study

This Biologics Contract Manufacturing market report studies market dynamics, status and outlook especially in North America, Europe and Asia-Pacific, Latin America, Middle East and Africa. This research report offers scenario and forecast (revenue/volume), and categorizes market by players, type, application, and region. This report also studies global market prominence, competitive landscape, market share, growth rate market dynamics such as drivers, restraints and opportunities, and distributors and sales channel.

This research study also integrates Industry Chain analysis and Porter’s Five Forces Analysis. Further, this report offers competitive scenario which comprises collaborations, market concentration rate and expansions, mergers & acquisitions undertaken by companies.

Final Report will add the analysis of the impact of COVID-19 on this industry.

Important years considered for this report:

Historical Years: 2017-2019

Base Year: 2020

Forecast Period: 2021-2027

Key Points Covered in Biologics Contract Manufacturing Market Survey

  • Demand will remain high in the U.S., backed by favourable reimbursement policies and presence of some of the leading market players.
  • Europe will continue showcasing high demand. Sales will remain high, especially in the U.K., Germany, France, and other countries.
  • China and India will exhibit high demand for Biologics Contract Manufacturing, backed by expanding healthcare sector.
  • Focus on research and development will increase in Brazil, creating opportunities for the expansion of the Biologics Contract Manufacturing market.
  • Hospitals are expected to showcase higher demand for Biologics Contract Manufacturing on account of greater access to advanced technologies and higher footfall of patients.
  • Driven by the presence of some of the leading pharmaceutical producers, demand in the Japan Biologics Contract Manufacturing market will continue increasing at a high pace.

Some of the key highlights covered in the report include:

  • Biologics Contract Manufacturing Market Demand-Supply Analysis -The report covers detailed insights into demand and supply forces prevailing in the global Biologics Contract Manufacturing market. It examines trends and factors influencing demand for Biologics Contract Manufacturing globally and gauges the impact of the same on the production.
  • Biologics Contract Manufacturing Pricing Analysis – The report presents exclusive pricing analysis. It compares pricing strategies adopted by the leading market players and identifies the most remunerative strategies.
  • Market Segmentation – The report segments the global market in terms of diverse criteria. It identifies the leading segment within each category and identifies growth drivers and restraints affecting growth across each segment.
  • Regional Analysis – The report segments the market in terms of North America, Europe, Latin America, Asia Pacific, and Rest of the World in terms of region. It has chapters exclusively dedicated to analyzing growth trends across each region. It identifies growth drivers as well challenges affecting demand for Biologics Contract Manufacturing across the world.
  • Competitive Analysis – Some of the leading market players are profiled in the report on Biologics Contract Manufacturing. The report offers estimation of share individually helps by the market players and determines the impact of some of their popular strategies.
  • COVID-19 Impact Analysis – This chapter is exclusively dedicated to gauging how the market has evolved or will develop in the post-pandemic era.
  • Growth Recommendations – In the end, the report presents valuable recommendations to ready businesses for unforeseen challenges in the near future.

Why should you invest in this report?

If you are aiming to enter the global Biologics Contract Manufacturing market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for Biologics Contract Manufacturing are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2027 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Download This Full Research Report, Click Here@

About Us

Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333



James Root

James Root have over 6+ years of experience working in business development, and customer retention. I’ve gained my experience through serving higher education, healthcare, automotive, aerospace, manufacturing, local government and hospitality businesses with technical solutions.

View all posts by James Root →

Leave a Reply

Your email address will not be published.